Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets

This article was originally published in The Pink Sheet Daily

Executive Summary

The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.

You may also be interested in...



Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor

Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.

Start-Up Quarterly Statistics, Q4 2012

Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.

Second GSK Neuro Spin-Out Targets Hearing Loss, Attracts Up To £10m

SV Life Sciences and Imperial Innovations pledge up to £10 million for GSK spin-out Autifony, the second to emerge from unwanted neurosciences R&D.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel